Home
ADVM
ADVM News

Latest Adverum Biotechnologies Inc. (ADVM) News on September 8, 2025

MT Newswires

2 months ago

Mizuho Cuts Price Target on Adverum Biotechnologies to $12 From $16, Keeps Outperform Rating

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Will Tesla have to play catch up to Waymo's robotaxis?

Yahoo Finance Video

3 months ago

Will Tesla have to play catch up to Waymo's robotaxis?

Why Scott Bessent wants to make it easier for banks to own Treasurys

Yahoo Finance

3 months ago

Why Scott Bessent wants to make it easier for banks to own Treasurys

EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry

GlobeNewswire

3 months ago

EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry

GlobeNewswire

3 months ago

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Thyme Care Triples Its Multidisciplinary Care Team with Increased Focus on Often-Overlooked Survivorship Population

PR Newswire

3 months ago

Thyme Care Triples Its Multidisciplinary Care Team with Increased Focus on Often-Overlooked Survivorship Population

Statement by Minister Guilbeault on Portuguese Heritage Month

CNW Group

3 months ago

Statement by Minister Guilbeault on Portuguese Heritage Month

Man Utd sign Brazil forward Cunha from Wolves

AFP

3 months ago

Man Utd sign Brazil forward Cunha from Wolves

‘All the crypto cowboys are gone’: Kevin O’Leary says the sector is safe now and is backing stablecoins

Moneywise

3 months ago

‘All the crypto cowboys are gone’: Kevin O’Leary says the sector is safe now and is backing stablecoins

MT Newswires

4 months ago

RBC Cuts Price Target on Adverum Biotechnologies to $4 From $5, Keeps Sector Perform, Speculative Risk

Associated Press Finance

4 months ago

Adverum Biotechnologies: Q1 Earnings Snapshot

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights

GlobeNewswire

4 months ago

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights

3 Penny Stocks Under $300M Market Cap To Consider

Simply Wall St.

4 months ago

3 Penny Stocks Under $300M Market Cap To Consider

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Argus Research

4 months ago

Daily – Vickers Top Buyers & Sellers for 04/29/2025

MT Newswires

4 months ago

Adverum Biotechnologies Insider Bought Shares Worth $1,048,950, According to a Recent SEC Filing

MT Newswires

5 months ago

Truist Removes $40 Price Target on Adverum Biotechnologies, Cites Share Volatility, Keeps Buy Rating

MT Newswires

5 months ago

RBC Cuts Price Target on Adverum Biotechnologies to $5 From $10, Keeps Sector Perform, Speculative Risk

Associated Press Finance

5 months ago

Adverum Biotechnologies: Q4 Earnings Snapshot

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones

GlobeNewswire

5 months ago

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference

GlobeNewswire

5 months ago

Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference

Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

GlobeNewswire

6 months ago

Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

MT Newswires

6 months ago

Adverum Biotechnologies Insider Bought Shares Worth $1,439,087, According to a Recent SEC Filing

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

GlobeNewswire

6 months ago

Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

3 US Penny Stocks With Market Caps Below $400M

Simply Wall St.

7 months ago

3 US Penny Stocks With Market Caps Below $400M

Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

GlobeNewswire

7 months ago

Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

9 months ago

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

10 months ago

Mizuho Securities Cuts Price Target on Adverum Biotechnologies to $16 From $20, Outperform Rating Maintained

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

10 months ago

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

10 months ago

Adverum Reports Positive Ixo-vec Data for Wet Age-Related Macular Degeneration; Shares Rise Pre-Bell

Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements

GlobeNewswire

10 months ago

Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

GlobeNewswire

10 months ago

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates

Zacks

10 months ago

Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates

Associated Press Finance

10 months ago

Adverum Biotechnologies: Q3 Earnings Snapshot

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

GlobeNewswire

10 months ago

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

GlobeNewswire

a year ago

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

Adverum Biotechnologies (ADVM) Upgraded to Strong Buy: What Does It Mean for the Stock?

Zacks

a year ago

Adverum Biotechnologies (ADVM) Upgraded to Strong Buy: What Does It Mean for the Stock?

Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic

Zacks

a year ago

Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

GlobeNewswire

a year ago

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High?

Zacks

a year ago

Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High?

MT Newswires

a year ago

Mizuho Trims Price Target on Adverum Biotechnologies to $20 From $22, Keeps Outperform Rating

MT Newswires

a year ago

Truist Adjusts Price Target on Adverum Biotechnologies to $40 From $60, Maintains Buy Rating

MT Newswires

a year ago

RBC Adjusts Price Target on Adverum Biotechnologies to $12 From $15, Maintains Sector Perform Rating, Speculative Risk

Associated Press Finance

a year ago

Adverum Biotechnologies: Q2 Earnings Snapshot

Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights

GlobeNewswire

a year ago

Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights

Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

GlobeNewswire

a year ago

Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for Ixo-vec for the Treatment of Wet AMD

GlobeNewswire

a year ago

Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for Ixo-vec for the Treatment of Wet AMD

MT Newswires

a year ago

Adverum Biotechnologies Insider Bought Shares Worth $613,470, According to a Recent SEC Filing

Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?

Zacks

a year ago

Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?

MT Newswires

a year ago

Chardan Research Adjusts Adverum Biotechnologies' PT to $40 From $4, Maintains Buy Rating

MT Newswires

a year ago

Adverum Reports Positive Interim Results in Study of Investigational Wet AMD Drug

Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

GlobeNewswire

a year ago

Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Wall Street Analysts Think Adverum Biotechnologies (ADVM) Could Surge 290.54%: Read This Before Placing a Bet

Zacks

a year ago

Wall Street Analysts Think Adverum Biotechnologies (ADVM) Could Surge 290.54%: Read This Before Placing a Bet

Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting

GlobeNewswire

a year ago

Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting

MT Newswires

a year ago

Oppenheimer Initiates Coverage on Adverum Biotechnologies With Outperform Rating, $25 Price Target

Adverum Biotechnologies to Participate in TD Cowen’s Genetic Medicines & RNA Summit

GlobeNewswire

a year ago

Adverum Biotechnologies to Participate in TD Cowen’s Genetic Medicines & RNA Summit

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

GuruFocus.com

a year ago

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

Energy Global

a year ago

ANDRITZ to equip new Silvan hydropower plant in Türkiye

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

USA TODAY

a year ago

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Business Wire

a year ago

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

Business Wire

a year ago

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

SEALSQ to Launch Two New Quantum Resistant Chips

GlobeNewswire

a year ago

SEALSQ to Launch Two New Quantum Resistant Chips

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Reuters

a year ago

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

GlobeNewswire

a year ago

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of Directors

GlobeNewswire

a year ago

Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of Directors

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

Yahoo Finance Video

a year ago

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

GlobeNewswire

a year ago

Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis

California seeks company profits in Big Oil climate lawsuit

Reuters

a year ago

California seeks company profits in Big Oil climate lawsuit

USA TODAY

a year ago

S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Business Wire

a year ago

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

GlobeNewswire

a year ago

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

GlobeNewswire

a year ago

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Business Wire

a year ago

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

GuruFocus.com

a year ago

Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress

Down -19.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)

Zacks

a year ago

Down -19.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)

Associated Press Finance

a year ago

Adverum Biotechnologies: Q1 Earnings Snapshot

Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights

GlobeNewswire

a year ago

Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights

Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?

Zacks

a year ago

Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?

Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

GlobeNewswire

a year ago

Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

a year ago

Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

MT Newswires

a year ago

HC Wainwright Starts Adverum Biotechnologies With Buy Rating, $30 Price Target

MT Newswires

a year ago

Mizuho Adjusts Price Target on Adverum Biotechnologies to $22 From $40 After Model Update, Maintains Buy Rating

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

GlobeNewswire

a year ago

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?

Zacks

a year ago

Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?

Down -24.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)

Zacks

a year ago

Down -24.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)

Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?

Zacks

a year ago

Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?

How Adverum (ADVM) Stock Stands Out in a Strong Industry

Zacks

a year ago

How Adverum (ADVM) Stock Stands Out in a Strong Industry

Down -28.72% in 4 Weeks, Here's Why Adverum Biotechnologies (ADVM) Looks Ripe for a Turnaround

Zacks

a year ago

Down -28.72% in 4 Weeks, Here's Why Adverum Biotechnologies (ADVM) Looks Ripe for a Turnaround

Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)

Zacks

a year ago

Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)

GuruFocus.com

a year ago

Adverum Biotechnologies Reports Encouraging Clinical Progress Amidst Financial Adjustments

Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?

Zacks

a year ago

Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?

Associated Press Finance

a year ago

Adverum Biotechnologies: Q4 Earnings Snapshot

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

GlobeNewswire

a year ago

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

Turn Pocket Change into Profit: 3 Penny Stocks Ready to Pop

InvestorPlace

2 years ago

Turn Pocket Change into Profit: 3 Penny Stocks Ready to Pop

Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

GlobeNewswire

2 years ago

Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

Stocks on the Launchpad: The Next 3 Market Sensations

InvestorPlace

2 years ago

Stocks on the Launchpad: The Next 3 Market Sensations

Share on Social Networks: